Harvard Apparatus Regenerative Technology Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2024	2023	2024	2023
Product revenue	$56	$—	$113	$—
Operating expenses:
Cost of sales	13	—	25	—
Research and development	642	1,566	1,482	2,075
Sales and marketing	197	55	312	55
General and administrative	1,685	1,030	2,796	3,408
Total operating expenses	2,537	2,651	4,615	5,538
Operating loss	(2,481)	(2,651)	(4,502)	(5,538)
Other (expense) income, net:
Other (expense) income, net	(17)	37	(26)	34
Net loss	(2,498)	(2,614)	(4,528)	(5,504)
Preferred stock dividends	—	3	—	(77)
Net loss attributable to common stockholders	$(2,498)	$(2,611)	$(4,528)	$(5,581)
Basic and diluted net loss per share attributable to common stockholders	$(0.18)	$(0.19)	$(0.32)	$(0.43)
Weighted average common shares outstanding, basic and diluted	14,258,511	13,785,657	14,102,918	13,000,211
Comprehensive loss:
Net loss	$(2,498)	$(2,614)	$(4,528)	$(5,504)
Foreign currency translation adjustments	(21)	—	(22)	—
Comprehensive loss	(2,519)	(2,614)	(4,550)	(5,504)
Less: Preferred stock dividends	—	3	—	(77)
Comprehensive loss attributable to common stockholders	$(2,519)	$(2,611)	$(4,550)	$(5,581)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.